Bank of America
MLYS icon

Bank of America’s Mineralys Therapeutics MLYS Stock Holding History

Bank of America’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.6M Buy
1,505,547
+405,175
+37% +$11.1M ﹤0.01% 1878
2026
Q1 		$29.8M Buy
1,100,372
+113,092
+11% +$3.32M ﹤0.01% 2042
2025
Q4 		$35.8M Buy
987,280
+219,015
+29% +$8.78M ﹤0.01% 1797
2025
Q3 		$29.1M Buy
768,265
+504,909
+192% +$10.9M ﹤0.01% 2224
2025
Q2 		$3.56M Buy
263,356
+116,134
+79% +$1.68M ﹤0.01% 4226
2025
Q1 		$2.34M Buy
147,222
+39,519
+37% +$455K ﹤0.01% 4545
2024
Q4 		$1.33M Buy
107,703
+11,549
+12% +$151K ﹤0.01% 4790
2024
Q3 		$1.16M Sell
96,154
-15,381
-14% -$186K ﹤0.01% 4954
2024
Q2 		$1.3M Buy
111,535
+29,077
+35% +$366K ﹤0.01% 4738
2024
Q1 		$1.06M Buy
82,458
+33,703
+69% +$416K ﹤0.01% 4893
2023
Q4 		$419K Buy
48,755
+35,496
+268% +$279K ﹤0.01% 5616
2023
Q3 		$126K Buy
13,259
+1,030
+8% +$13.4K ﹤0.01% 6146
2023
Q2 		$209K Sell
12,229
-1,761
-13% -$26.3K ﹤0.01% 5802
2023
Q1 		$219K Buy
+13,990
New +$236K ﹤0.01% 5877

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America's MLYS Position: Q2 2026 in Review

Bank of America increased its Mineralys Therapeutics (MLYS) stake by 37% in Q2 2026, buying an estimated $11.1M and bringing the position to 1,505,547 shares worth $40.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

Bank of America first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Bank of America held 1,505,547 shares of Mineralys Therapeutics worth $40.6M as of Q2 2026.
  • Bank of America bought 405,175 Mineralys Therapeutics shares in Q2 2026, an estimated $11.1M.
  • Mineralys Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1878 holding.
  • Bank of America first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.